Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome
13 déc. 2023 08h30 HE
|
Quoin Pharmaceuticals, Inc.
Positive initial data and clean safety profile catalyze optimization planSize of both ongoing clinical trials significantly increasedLower dose eliminated from blinded trialDosing frequency changed to...